- Home
- SKIL vs ALGS Comparison
SKIL vs ALGS Comparison
Compare SKIL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIL | ALGS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | 2247 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 33.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKIL | ALGS |
|---|---|---|
| Price | $5.17 | $5.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 107.3K | 74.6K |
| Earning Date | 04-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $0.11 | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.43 | $4.80 |
| 52 Week High | $18.45 | $13.69 |
Technical Indicators
Market Signals| Indicator | SKIL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 55.37 |
| Support Level | $4.83 | $4.80 |
| Resistance Level | $8.36 | $5.94 |
| Average True Range (ATR) | 0.86 | 0.39 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 11.65 | 86.41 |
Price Performance
Historical ComparisonAbout SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.